Skip to content
  • Home
  • World News
  • Business
  • Aviation
195 news

195News

All the news that's fit to print

  • Home
  • World News
  • Business
  • Aviation
  • Toggle search form
  • Day 329 – Latynina.tv – Alexey Arestovych
    Day 329 – Latynina.tv – Alexey Arestovych World News
  • “More lives ruined and lost”
    “More lives ruined and lost” Business
  • Midwest Institute for Non-Surgical Therapy (MINT) Introduces New Therapy to Treat Men With Enlarged Prostates
    Midwest Institute for Non-Surgical Therapy (MINT) Introduces New Therapy to Treat Men With Enlarged Prostates Business
  • Secretary Antony J. Blinken and Israeli Prime Minister Benjamin Netanyahu After Their Meeting
    Secretary Antony J. Blinken and Israeli Prime Minister Benjamin Netanyahu After Their Meeting World News
  • War in Ukraine, Analytics. Day 1229: Why American Aid Will Not Help. Arestovych, Shelest.
    War in Ukraine, Analytics. Day 1229: Why American Aid Will Not Help. Arestovych, Shelest. World News
  • Goodable and Captivate Announce a New Partnership
    Goodable and Captivate Announce a New Partnership Business
  • The Pickleball Club Celebrates Groundbreaking for Port St. Lucie Club
    The Pickleball Club Celebrates Groundbreaking for Port St. Lucie Club Business
  • FAA Rolls Out New Technology for Controllers to Improve Surface Safety at the Nation’s Airports
    FAA Rolls Out New Technology for Controllers to Improve Surface Safety at the Nation’s Airports Aviation
Solaris Endovascular, Inc. Launches to Revolutionize Vascular Health Solutions Globally

Solaris Endovascular, Inc. Launches to Revolutionize Vascular Health Solutions Globally

Posted on November 15, 2024 By NewsEditor

Solaris Endovascular, Inc. Launches to Revolutionize Vascular Health Solutions Globally

Solaris Endovascular Inc

Solaris SX is very flexible

Solaris SX Flexibility

NEW ORLEANS, LA, UNITED STATES, November 13, 2024 /EINPresswire.com/ — Solaris Endovascular, Inc. Launching to Address Vascular Health Challenges Globally

Solaris Endovascular, Inc. proudly announces its formation to develop solutions for Dialysis Access and Peripheral Artery Disease (PAD). Solaris Endovascular develops evidence-based technologies, intended to treat and extend the patency of dialysis access fistulae, grafts, and peripheral arteries to allow patients to lead healthier lives with fewer interventions.

End-Stage Kidney Disease (ESKD) is a major health concern affecting approximately 10 million people worldwide with approximately 3 million people receiving kidney replacement therapy and relying on hemodialysis to survive. Over 50% of these patients experience vascular access failures within the first year and are subjected to hospital admissions and repeated costly endovascular or surgical interventions to restore their lifeline to dialysis—this drastically impacts quality of life, treatment effectiveness and survival.

In April 2024, the American Heart Association reported that the global prevalence of peripheral artery disease (PAD) may be as high as 230 million people. PAD can progress from painful walking to critical limb ischemia, and many patients require revascularization procedures to restore blood flow, improve symptoms, or prevent amputations.

Stent-grafts are emerging as the preferred minimally invasive treatment for these conditions and Solaris Endovascular is currently selling the latest generation of stent-grafts. The flagship Solaris(TM) SX Vascular Stent Graft employs the most advanced electrospinning PTFE impermeable membrane that prevents tissue ingrowth, maximizes patency, and reduces restenosis. This thin, multi-directional PTFE membrane encapsulates a nitinol stent that provides flexibility, high radial strength, and crush resistance for optimal blood flow. These features are already proven in global markets with more than 13,000 units sold to date. Interventional and endovascular physicians worldwide have chosen Solaris SX for its trackability and precise pinpoint deployment, ensuring accurate placement.

“Bringing this innovative technology to the United States is a major step forward in improving the lives of patients,” said Dr. Marco Costa, Chairman and Chief Medical & Scientific Officer at Solaris Endovascular Inc. “Solaris Endovascular’s advanced covered stent platforms will not only reduce the burden of repeated interventions but will also dramatically enhance the quality of life and life expectancy for those who suffer from these debilitating conditions.”

Looking ahead, Solaris Endovascular is already enrolling patients in clinical trials for the first of its kind Solaris(TM) DE Drug-Eluting Vascular Stent Graft – that will address the remaining unmet need in covered stents: edge stenosis. Solaris DE incorporates Sirolimus, a powerful and safe anti-proliferative agent that revolutionized the treatment of coronary artery disease with the virtual elimination of restenosis, from 30% to 3%.

“We expect Solaris DE to deliver similar transformative results to patients with ESKD and PAD,” said Dr. Costa.

CEO Randy Hubbell emphasized the company’s unique position in the market: “Solaris Endovascular represents a rare opportunity to start a new company that is revenue producing from the beginning, has a decade-plus manufacturing expertise in stents, stent grafts and endovascular drug delivery, and a proven product supported by clinical studies in multiple markets before entering the U.S. Our platform addresses a significant unmet need in both dialysis access and PAD, offering life-changing solutions for patients while setting a new standard in endovascular care.”

As Solaris Endovascular prepares for the U.S. registration process, it is committed to driving meaningful improvements in patient outcomes, reducing hospital readmissions, and lowering overall healthcare costs.

About Solaris Endovascular, Inc.

Solaris Endovascular, Inc. is a growth stage US-based medical device company developing advanced endovascular solutions for patients suffering from dialysis access challenges and Peripheral Artery Disease. With a proven stent platform and innovative drug-eluting technology, led by seasoned executives with extensive experience in cardiovascular MedTech, Solaris Endovascular is uniquely positioned and committed to improving long-term patient outcomes and transforming vascular health.

For more information, please visit: [www.solarisendovascular.com]

Randy Hubbell
Solaris Endovascular, Inc.
[email protected]
Visit us on social media:
LinkedIn

Legal Disclaimer:

EIN Presswire provides this news content “as is” without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

You just read:

News Provided By

November 13, 2024, 13:30 GMT

Distribution channels:
Agriculture, Farming & Forestry Industry, Banking, Finance & Investment Industry, Beauty & Hair Care, Business & Economy, Chemical Industry, Companies, Conferences & Trade Fairs, Culture, Society & Lifestyle, Education, Emergency Services …


EIN Presswire’s priority is author transparency. We do our best to weed out false and misleading content. The content above is
the sole responsibility of the author who makes it available. If you have any complaints, kindly contact the author above.

Article originally published on www.einpresswire.com as Solaris Endovascular, Inc. Launches to Revolutionize Vascular Health Solutions Globally

Business

Post navigation

Previous Post: Maria Cecilia Conder selected as Top Board Member of the Year in Fine Arts by IAOTP
Next Post: Tech and Social Impact Leaders Converge at Goodera’s AI for Impact Summit

Related Posts

  • Gb Sciences’ Plant-based Formulations Designed to Treat Anxiety Achieve Statistical Significance in Animal Study
    Gb Sciences’ Plant-based Formulations Designed to Treat Anxiety Achieve Statistical Significance in Animal Study Business
  • HackerNoon Launches Onsite Polls and Tech Company News Reports
    HackerNoon Launches Onsite Polls and Tech Company News Reports Business
  • Questions raised over safety of planned Rosatom nuclear power plants in Uzbekistan.
    Questions raised over safety of planned Rosatom nuclear power plants in Uzbekistan. Business
  • A New Destination for Instrumental Music Lovers
    A New Destination for Instrumental Music Lovers Business
  • Tattoo Vanish Method Offers Natural Alternative to Laser Tattoo Removal with Fewer Treatments
    Tattoo Vanish Method Offers Natural Alternative to Laser Tattoo Removal with Fewer Treatments Business
  • FPW Media Announces Ranking on Adweek’s 2022 Fastest Growing Agencies
    FPW Media Announces Ranking on Adweek’s 2022 Fastest Growing Agencies Business
September 2025
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
2930  
« Aug    
last celebrity gossip
Gossip Stone - celebrity life and gossip

Recent Posts

  • Louisiana’s First Dedicated Residential Eating Disorder Treatment Center for Women Opens Near New OrleansSeptember 1, 2025
  • Purpose-Built Model C2 Variant for Large Material HandlingAugust 31, 2025
  • LATIFF 2025 Sets New Standard for International Film Festivals with Impact-Driven Cinema and World-Class HonorsAugust 31, 2025
  • Akropin Unveils Insights on How AI Is Shaping the Future of MarketingAugust 31, 2025
  • Aviation (MRO) Market Size to Reach $145.28 Billion by 2034, Sustained by 4.82% CAGRAugust 30, 2025
Brand Values Content
VUGA Enterprises - media network PR & Marketing
  • Cybernews Business Digital Index Finds Only 11% of Companies Earn Top Cybersecurity Grades
    Cybernews Business Digital Index Finds Only 11% of Companies Earn Top Cybersecurity Grades Business
  • Nicole’s story: the child victims of UK drug gangs – BBC News
    Nicole’s story: the child victims of UK drug gangs – BBC News World News
  • Inmedix appoints Lucy Lu as CCO as it approaches US commercialization.
    Inmedix appoints Lucy Lu as CCO as it approaches US commercialization. Business
  • War Day 237: war diaries w/Advisor to Ukraine President, Intel Officer @arestovych & #Feygin
    War Day 237: war diaries w/Advisor to Ukraine President, Intel Officer @arestovych & #Feygin World News
  • Acting Assistant Secretary for Democracy, Human Rights, and Labor Erin Barclay on the 2022 Country Reports on Human Rights Practices
    Acting Assistant Secretary for Democracy, Human Rights, and Labor Erin Barclay on the 2022 Country Reports on Human Rights Practices World News
  • Fobi AI Announces Private Placement of Units for Aggregate Gross Proceeds of Up To C,000,000
    Fobi AI Announces Private Placement of Units for Aggregate Gross Proceeds of Up To C$2,000,000 Business
  • SAUDI ‘QUICK COMMERCE’ STARTUP NINJA LEAPS OUT OF STEALTH WITH A MEGA SEED ROUND AND A CLEAR PATH TO SUSTAINABILITY
    SAUDI ‘QUICK COMMERCE’ STARTUP NINJA LEAPS OUT OF STEALTH WITH A MEGA SEED ROUND AND A CLEAR PATH TO SUSTAINABILITY World News
  • Ocular Hypertension Market Size Expected to Reach US$ 4,446.4 Million by 2033
    Ocular Hypertension Market Size Expected to Reach US$ 4,446.4 Million by 2033 Business
aerospace company
stem cell clinic in kiev
medical spa in miami
Fashion TV free

Copyright © 2023 195 News. All Rights Reserved by Coolaser | Partner of VUGA Enterprises |  Advertising: Get Published

Powered by .